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INTRODUCTION
Stenotrophomonas maltophilia (S. maltophilia) is a Gram-neg-
ative aerobic bacillus (1) that is increasingly recognized as
an important cause of nosocomial infection, especially in
debilitated and immunocompromised hosts (2-6). It is asso-
ciated with significant morbidity and mortality rates. Infec-
tive endocarditis due to this organism is rare. A review of the
literature revealed only 24 cases including one case in Korea.
Prosthetic valves are more commonly associated than native
valves. S. maltophilia is characterized by its resistance to many
currently used antimicrobial agents (7, 8). We experienced
a case of repetitive S. maltophilia endocarditis following
mitral valve prosthesis implantation in an apparently im-
munocompetent man.
CASE REPORTS
A 44-yr-old man was admitted to our hospital in June
1998 with a 10-day history of fever and chills. In 1993, the
patient had undergone 27 mm Carbo Medics metallic mitral
valve replacement for severe rheumatic valvular disease. No
other underlying disease was found. His medical history
revealed no predisposing event such as dental procedures or
injections of intravenous drugs. On physical examination,
blood pressure was 110/70 mmHg, pulse rate 85/min, and
body temperature 38℃. He was not so ill in appearance and
cardiac examination revealed normal S1, S2 with metallic
heart sound. There was no audible murmur. The remainder
of the physical examination was unremarkable. 
Laboratory tests showed that white blood cell (WBC)
10,500/ L, erythrocyte sedimentation rate (ESR) 52 mm/hr,
and C-reactive protein (CRP) 5.56 mm/dL. Rheumatoid
factor was positive (35.6 mm/dL) and urinalysis were normal.
Increased cardiothoracic ratio was observed on chest radiog-
raphy. Electrocardiogram revealed a normal sinus rhythm.
The transthoracic echocardiogram demonstrated suspicious
vegetation on prosthetic mitral valve. The transesophageal
echocardiogram revealed thread-like structure on the poste-
rior leaflet of mitral annulus. The patient was begun on a
regimen of vancomycin (15 mg/kg q 12 hr) and gentamicin
(1 mg/kg q 8 hr) before the sensitivity report (Table 1). S.
maltophilia was identified on blood culture. We did not change
the antibiotics because he became afebrile and improved
clinically. Also, there was the possibility of laboratory con-
tamination because S. maltophilia was isolated only once
among six blood culture sets. After three weeks’ antibiotic
therapy, the patient was transferred to another hospital and
continued the therapy for another week. 
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Two Episodes of Stenotrophomonas maltophilia Endocarditis of 
Prosthetic Mitral Valve
: Report of a Case and Review of the Literature
Stenotrophomonas maltophilia (previously named Xanthomonas maltophilia) is
an aerobic, non-fermentive, Gram-negative bacillus that is wide spread in the
environment. It was considered to be an organism with limited pathogenic poten-
tial, which was rarely capable of causing diseases in human other than those
who were in debilitated or immunocompromised state. More recent studies have
established that Stenotrophomonas maltophilia can behave as a true pathogen.
Endocarditis due to this organism is rare, and only 24 cases of Stenotrophomonas
maltophilia endocarditis have been reported in the medical literature. Most cases
were associated with risk factors, including intravenous drug abuse, dental treat-
ment, infected intravenous devices, and previous cardiac surgery. We present a
case with two episodes of Stenotrophomonas maltophilia endocarditis after mitral
valve prosthesis implantation, which was treated with antibiotics initially, and a
combination of antibiotics and surgery later. To our knowledge, this is the first
case of repetitive endocarditis due to Stenotrophomonas maltophilia.
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In December 2000, he was hospitalized again due to fever,
myalgia, and anorexia for one month. One month before
admission, there was an episode of dysarthria, dysphagia
and drooling for 1 day, which was assumed to be a transient
ischemic attack. He visited our hospital because fever and
myalgia persisted despite 1 month therapy with vancomycin
and gentamicin in another hospital. Laboratory data includ-
ed a WBC count of 6,400/ L, ESR 90 mm/hr, and CRP
5.56 mg/dL. Urinalysis showed three to five red blood cells
per high-power field. The transesophageal echocardiogram
showed a thread-like structure attached to the rim of the
prosthetic mitral valve (Fig. 1). There was no evidence of
mitral regurgitation, perivalvular abscess, or new partial
dehiscence of the prosthetic valve. S. maltophilia was isolated
from 6 blood culture sets. We assumed that S. maltophilia
was colonized somewhere in the body and reinfection had
occurred. On the basis of sensitivity profile (Table 1), a regi-
men of trimethoprim-sulfamethoxazole (400 mg/80 mg q 8
hr) and tobramycin (1.7 mg/kg q 8 hr) was used. Because of
deterioration of renal function, tobramycin was discontin-
ued and trimethoprim-sulfamethoxazole was reduced (9, 10).
Because there was a history of transient ischemic attack,
surgical replacement of the prosthetic valve was undergone
on the 9th day after beginning of antibiotics. There was a
material which seemed like a vegetation on the posterior
leaflet of the mitral valve. No organism was isolated from
culture of the mitral valve vegetation. He was discharged
after six weeks of antibiotic therapy (trimethoprim-sul-
famethoxazole). The patient remained afebrile and asymp-
tomatic for 2 months after he was discharged.
DISCUSSION
Previously named Xanthomonas maltophilia or Pseudomonas
maltophilia has now been classified as Stenotrophomonas mal-
tophilia, within which S. maltophilia is the only species (1).
The genus was proposed by Palleroni and Brandbury in 1993
following many years of uncertain taxonomic position of
this organism. S. maltophilia is an aerobic, non-fermentive,
Gram-negative bacillus with 0.5 to 1.5  m length (1, 3). It
has been isolated from blood, respiratory secretion, urine,
wound, cerebrospinal fluid, pericardial fluid, and pus (11).
The organism may be isolated without clinical evidence of
infection (12). When the organism is isolated from clinical
specimens such as sputum, it is important to distinguish
colonization from infection because true infection requires
antimicrobial therapy (2). Culture of S. maltophilia from
normally sterile specimens such as blood or cerebrospinal
fluid must be considered as true infection beyond no doubt.
Although it is an infrequent human pathogen, it has been
reported as a causal agent in bacteremia, endocarditis, respi-
ratory tract infection, central nervous system infection, oph-
thalmologic infection, urinary tract infection, gastrointesti-
nal infection, skin, soft tissue, bone and joint infections (2-
4, 13). Potential risk factors for infection of S. maltophilia
are malignancies (5), prior therapy with broad-spectrum
antibiotics (6), chronic respiratory disease (6), prolonged
endotracheal intubation (4, 6), and indwelling vascular
catheters (14). 
S. maltophilia endocarditis is a rare disease. Most of the cases
are associated with risk factors, including intravenous drug
abuse, prosthetic valve surgery, dental treatment, and con-
taminated intravascular devices. Endocarditis in prosthetic
valve is more common than in native valves. The prognosis
of S. maltophilia endocarditis is variable. Favorable outcome
with antimicrobial therapy alone has been reported (15) and
surgery to replace the infected valve may be necessary (16).
In reviewing of the literature, only 15 of 24 (63%) patients
Amikacin S R
Ampicillin R R
Ampicillin/sulbactam R
Cefazolin R
Cefepime R
Cefotaxime R
Cefotetan R R
Ceftazidime R
Ceftriaxone R
Cephalothin R
Ciprofloxacin R I
Gentamicin S S
Imipenem R R
Ofloxacin S
Piperacillin R R
Tobramycin S S
Trimethoprim/sulfamethoxazole S S
Table 1. Antibiotic susceptibility of Stenotrophomonas mal-
tophilia isolated from blood cultures of 1998 and 2000
1998 2000 Drugs
I, intermediate; S, sensitive; R, resistant
Fig. 1. Transesophageal echocardiogram showed a thread like
structure attached to the rim of the prosthetic mitral valve.
PMV: Prosthetic mitral valve, LA: Left atrium.
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reported survived. Seven of the survivors (47%) had under-
gone valve replacement. Six of 10 (60%) patients who were
treated only medically survived. 
An important clinical aspect of S. maltophilia is its diffi-
culty to treat due to the resistance nature of the organism
(17). Most strains of S. maltophilia are resistant to  -lactam
agents due to two mechanisms, low outer membrane per-
meability and constitutive overproduction of  -lactamases
(18, 19). Furthermore, a slow growth rate and an increased
mutation rate can generate discordance between the in vitro
susceptibility testing and clinical outcome (7). Standard in
vitro susceptibility methods are not completely reliable for
detecting resistant strains of S. maltophilia: therefore, these
results should be cautiously interpreted (7). The antibiotic
therapy of choice for S. maltophilia endocarditis is not known
and largely empiric. In vitro data suggest that trimethoprim-
sulfamethoxazole, ticarcillin-clavulanate, and cirpofloxacin
are effective agents. Trimethoprim-sulfamethoxazole and
aminoglycoside were used the most commonly. In this case,
vancomycin and gentamicin were used during the first epi-
sode. It seems to have been effective because there was at least
one effective antibiotics (gentamicin) and the bacterial bur-
den was small, assumed from the fact that S. maltophilia grew
in only once from 6 blood culture sets. During the second
episode, the same regimen was administered for one month
in another hospital. There was probably a greater bacterial
burden, also assumed from the fact that S. maltophilia grew in
all 6 blood culture sets even though in the absence of quan-
titative tests of this organism. This might be one reason why
the regimen was ineffective.
In summary, S. maltophilia has emerged as a nosocomial
pathogen, especially in immunocompromised or debilitated
host. Infective endocarditis associated with this organism is a
rare disease and carries a high mortality rate. When S. mal-
tophilia was isolated from blood in the patients with risk
factors even in non-nosocomial conditions, one should seri-
ously consider the possibility of S. maltophilia endocarditis.
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